Study: Gut microbe-generated phenylacetylglutamine is an endogenous allosteric modulator of β2-adrenergic receptors . Image Credit: Explode / Shutterstock.com Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and heart failure (HF).
In a recent study published in tjournal Nature Communications , researchers examine the mechanisms involved in the association between PAGln and adverse cardiovascular outcomes. Exploring new ways to treat CVDs Chronic non-communicable diseases are responsible for almost 75% of deaths worldwide. CVDs, HF, and their comorbidities comprise a significant proportion of human mortality, thus emphasizing the urgent need for improving current diagnostic and therapeutic capabilities.
As research advances, the relationship between diet, gut microbiota, and public health is becoming increasingly evident. A growing body of literature highlights the association between gut microbial assemblages and psychological outcomes, including obesity, diabetes, and CVD risk. PAGln has been hypothesized in several studies to correlate with adverse cardiovascular events.
In fact, some studies have even used circulating and fecal concentrations of PAGln as proxies for predicting future CVD risk. Nevertheless, the associations and mechanisms involved in the relationships between PAGln and CVD remain unclear. Verifying and elucida.